The objective of this study is to assess the efficacy and safety of rituximab combining with low-dose mycophenolate mofetil in the induction therapy of proliferative lupus nephritis in children.
Children aged 3-18 years old, regardless of sex;
SLE patients who meet the 2019 EULAR/ACR SLE criteria or the 2012 SLICC diagnostic criteria;
Diagnosed as lupus nephritis and the classification was consistent with proliferative lupus nephritis (type III or IV, with or without type V);
White blood cell count ≥3.0×10^9/L, and lymphocyte count ≥ 0.5× 10^9/L and CD20 (or CD19)≥1/ul;
Patients with lupus encephalopathy;
Estimated GFR<60ml/min/1.73m²(Swchartz formula);
HBV-antigen positive, HCV or HIV antibody positive;
Severe infection (including chronic hepatitis, EB virus or cytomegalovirus infection) and tuberculosis;